NASDAQ •
Healthcare •
Drug Manufacturers - Specialty & Generic •
Quote as of 05/13/2026 14:28
Company Profile
IndustryDrug Manufacturers - Specialty & Generic
SectorHealthcare
ExchangeNASDAQ
Market Capitalization2,217.57 mln
Float222 mln
Earnings Date08/10/2026
Piotroski F-Score
7
/ 9
Strong
Beneish M-Score
-2.16
Caution advised
1-Year Forecast
21.50
Transformational upside
Relative Strength
78
/ 100
Strongly outperforming
Debt / Equity
-3.68
Negative equity
Pre-Tax Margin
39%
Very strong margin
Business Description
BioCryst Pharmaceuticals is a drug development company based in Durham, North Carolina, focused on creating treatments for rare and serious medical conditions. Its main products include ORLADEYO, a pill for hereditary angioedema, and RAPIVAB, an intravenous flu treatment. The company also has several drugs in clinical trials targeting conditions such as Netherton syndrome, diabetic eye disease, and atopic dermatitis. BioCryst works with a range of partners including pharmaceutical companies, government health agencies, and academic institutions to advance its research.
